{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T21:02:53Z","timestamp":1786568573164,"version":"build-2736575974"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2006,10,12]],"date-time":"2006-10-12T00:00:00Z","timestamp":1160611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2006,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:styled-content>Objectives<\/jats:styled-content>: The purpose of this study was to evaluate the efficacy and safety of device closure of patent foramen ovale (PFO) versus antiplatelet therapy in patients with cryptogenic stroke (CS). <jats:styled-content>Background<\/jats:styled-content>: There are no controlled data to support the therapeutic value of PFO closure with a device compared to medical treatment in patients with CS. <jats:styled-content>Methods<\/jats:styled-content>: We performed a nonrandomized, prospective, patient preference case series comparing the recurrence rate in 92 patients with PFO and CS who were treated either with antiplatelet agents (44 patients) or underwent catheter closure (48 patients) using the Amplatzer PFO occluder (APFOO). All patients completed a 2\u2010year follow\u2010up. <jats:styled-content>Results<\/jats:styled-content>: PFO closure group. Immediate complete closure (CC) was observed in 44\/48 (91%) patients. Four (9%) patients had a minimal residual shunt immediately after the procedure. One patient developed hemopericardium that was successfully managed by pericardiocentesis. No other complication was observed. Follow\u2010up. PFO closure group. Contrast bubble study at 6\u2010month follow\u2010up confirmed CC in all 48 patients. No complications were observed. Antiplatelet therapy group. Three (6%) and 6 (13%) patients had a major and minor hemorrhagic event, respectively. The average incidence of embolic events\/year was 0 and 14.75% for the PFO closure group and the antiplatelet therapy group, respectively (<jats:italic>P<\/jats:italic> &lt; 0.001). <jats:styled-content>Conclusions<\/jats:styled-content>: PFO closure using the APFOO is a rational alternative to medical treatment in patients with CS. Larger randomized clinical trials are required to support the use of this device over the other PFO occluders and medical therapy. \u00a9 2006 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ccd.20868","type":"journal-article","created":{"date-parts":[[2006,10,13]],"date-time":"2006-10-13T01:34:05Z","timestamp":1160703245000},"page":"741-746","source":"Crossref","is-referenced-by-count":40,"title":["Transcatheter closure versus medical therapy of patent foramen ovale and cryptogenic stroke"],"prefix":"10.1002","volume":"68","author":[{"given":"Basil (Vasilios) D.","family":"Thanopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petros D.","family":"Dardas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Karanasios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholaos","family":"Mezilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,10,25]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805053181802"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)92944-3"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.9.950"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)60336-X"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.107.6.1504"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.29.5.944"},{"key":"e_1_2_6_8_2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1212\/WNL.55.8.1172","article-title":"Interatrial septal abnormalities and stroke. A meta\u2010analysis of case\u2010control studies","volume":"55","author":"Overrell JR","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199709043371005"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.25.4.782"},{"key":"e_1_2_6_11_2","first-page":"57","article-title":"Prevention of recurrent cerebral ischemic events in patients with patent foramen ovale and cryptogenic strokes or transient ischemic attacks","volume":"15","author":"Cujec B","year":"1999","journal-title":"Can J Cardiol"},{"key":"e_1_2_6_12_2","first-page":"54","article-title":"Devices to reduce stroke","author":"Murat TE","year":"2004","journal-title":"J Invasive Cardiol"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2004.01.012"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.08.038"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011258"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-9-200311040-00010"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.86.6.1902"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)90405-1"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.8.893"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)01904-6"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000027819.19722.EE"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10067"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-726X(200006)50:2<195::AID-CCD11>3.0.CO;2-F"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410250410"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.05.044"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10674"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.10.021"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000019069.32964.0E"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2004.052258"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.10577"},{"key":"e_1_2_6_31_2","first-page":"II","article-title":"Adverse effects associated with nickel allergy in patients undergoing percutaneous atrial septal defect or patent foramen ovale closure","volume":"112","author":"Wertman B","year":"2005","journal-title":"Circulation"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16721-4"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fccd.20868","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.20868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T19:36:37Z","timestamp":1700076997000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.20868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,25]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["10.1002\/ccd.20868"],"URL":"https:\/\/doi.org\/10.1002\/ccd.20868","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,25]]}}}